IP Library › Granted Patent US 10,611,758
Granted Patent B2
US 10,611,758 · App. 16/460,630 · Granted Apr 7, 2020

N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

Inventors: Rebecca Louise Davie (Salisbury, GB); Hannah Joy Edwards (Salisbury, GB); David Michael Evans (Salisbury, GB); Simon Teanby Hodgson (Bedfordshire, GB)
Assignee: Kalvista Pharmaceuticals Limited
C07D413/14A61K31/445A61K31/4439A61K31/496A61P43/00C07D231/14C07D401/06C07D401/10C07D401/14C07D403/10C07D409/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,611,758
App. No.
16/460,630
Granted
Apr 7, 2020
Kind
B2
Abstract

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Claims (1)

1. A method of treating a disease or condition in which plasma kallikrein activity is implicated, comprising administration to a subject in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein the disease or condition in which plasma kallikrein activity is implicated is hereditary angioedema, and wherein the compound of Formula (I) is:

Assignments (4)
ASSIGNMENT OF SECURITY INTEREST Recorded Jan 15, 2026
From: KALVISTA PHARMACEUTICALS LIMITED; DRI HEALTHCARE ACQUISITION LP
To: DRI UK LP
Reel/Frame 074410/0366 →
SECOND AMENDMENT TO THE PURCHASE AND SALE AGREEMENT DATED MAY 22, 2025 Recorded Jan 15, 2026
From: DRI HEALTHCARE ACQUISITIONS LP; KALVISTA PHARMACEUTICALS LIMITED; KALVISTA PHARMACEUTICALS INC.
To: DRI UK LP
Reel/Frame 074387/0900 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2026
From: DRI HEALTHCARE ACQUISITIONS LP
To: DRI UK LP
Reel/Frame 073489/0961 →
SECURITY INTEREST Recorded Nov 11, 2024
From: KALVISTA PHARMACEUTICALS LIMITED
To: DRI HEALTHCARE ACQUISITIONS LP
Reel/Frame 069334/0267 →
Priority Claims (1)
GB 1421083.5 · Nov 27, 2014 · national
Continuity (2)
Division 15527923
Related Publication 20190330200A1 · Oct 31, 2019